Learn more →
Back to Expert Scholars
Cell Therapy / 细胞治疗Multiple Myeloma

Amrita Krishnan

阿姆里塔·克里希南

MD

🏢City of Hope Comprehensive Cancer Center(希望之城综合癌症中心)🌐USA

Director, Judy and Bernard Briskin Center for Multiple Myeloma Research多发性骨髓瘤研究中心主任

52
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Amrita Krishnan directs the myeloma program at City of Hope and is a national leader in stem cell transplantation and cellular therapy for myeloma. She has pioneered allogeneic SCT approaches and contributed to advancing CAR-T manufacturing platforms at a high-volume transplant center.

Share:

🧪Research Fields 研究领域

Multiple Myeloma多发性骨髓瘤
Allogeneic SCT异体造血干细胞移植
CAR-T ManufacturingCAR-T制造
Stem Cell Transplantation干细胞移植

🎓Key Contributions 主要贡献

Allogeneic SCT in Myeloma

Investigated the role of allogeneic stem cell transplantation including reduced-intensity conditioning regimens in relapsed/refractory myeloma, defining patient populations likely to benefit from graft-versus-myeloma effects.

CAR-T Manufacturing and Logistics

Led City of Hope initiatives optimizing the manufacturing pipeline, vein-to-vein time, and bridging therapy strategies for BCMA-directed CAR-T therapies in heavily pretreated myeloma patients.

Novel Conditioning Regimens for Myeloma Transplant

Developed and tested novel conditioning regimens incorporating targeted radionuclide therapy and novel agents to reduce disease burden prior to autologous and allogeneic transplantation in high-risk myeloma.

Representative Works 代表性著作

[1]

Allogeneic Transplantation for Multiple Myeloma: Outcomes and Predictors

Biology of Blood and Marrow Transplantation (2020)

Analysis of long-term outcomes after allogeneic SCT for myeloma, identifying prognostic factors for disease control and survival.

[2]

CAR-T Cell Therapy in Myeloma: Practical Considerations for High-Volume Centers

Transplantation and Cellular Therapy (2022)

Operational framework for implementing commercial BCMA CAR-T programs at large academic transplant centers.

[3]

Optimizing Bridging Therapy Prior to BCMA CAR-T in Relapsed Myeloma

Blood Advances (2023)

Retrospective analysis examining impact of bridging therapy choice on CAR-T expansion and clinical outcomes in myeloma patients.

🏆Awards & Recognition 奖项与荣誉

🏆American Society for Transplantation and Cellular Therapy Distinguished Service Award
🏆International Myeloma Foundation Innovation Award
🏆City of Hope Physician Scientist Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 阿姆里塔·克里希南 的研究动态

Follow Amrita Krishnan's research updates

留下邮箱,当我们发布与 Amrita Krishnan(City of Hope Comprehensive Cancer Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment